Isis - Addressing Some Of The Bull Arguments To My Short Thesis
- Big pharma partnership does not ensure success.
- Isis management tends to err on the side of omission in data release.
- There isn't enough data from newer short-term antisense studies to derive long-term safety conclusions.
- Even an optimal ISIS 2.0 sequence can still generate an immune response in mice.